Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: KLH who wrote (703)	5/13/1999 9:19:00 AM
From: StockMiser	Read Replies (3) \| Respond to of 2344

Huge amounts of room KLH. That would be MATX, which is really just conventional chemo injected into tumors, and it's for head/neck. Remember that with BIOM you have a NOVEL approach to treatment that is both effective and elegant. It will also work in conjunction with other therapies, and work on multiple cancer types. The market is huge, and Biomira will be one of the first approved novel therapies coming out of the new biotech industry. I would expect Biomira shares to at least double from where ever they are at the time of FDA fast track approval :-) (And I expect us trading above 12 by then too) SM